Recent observations, arising largely from the introduction of methods for measuring 1,25 dihydroxyvitamin D s levels in plasma, (1, 2) have cast some doubt on the pathogenesis, prevention, and therapy of osteomalacia. Thus although most patients with abnormal vitamin D 3 metabolism have 1,25 (OH)2 D 3 levels in the expected range, some notable exceptions have been described. In some patients with osteomalacia, for instance, Jubiz et al (3) found that 1,25 (OH)2 D s levels were normal or even increased when one would have expected them to be low. These observations are difficult to reconcile with previous experimental animal work showing that 1,25 (OH)2 D 3 in small doses was ten times more effective than vitamin D s in the prevention and treatment of rickets (4).
Furthermore, even before the introduction of methods for measuring 1,25 (OH)2 Ds-it was emphasized that in some cases where plasma levels would be predicted to be absent or low, osteomalacia was absent or very slight. Thus in 1975 Ellis and Peart (5) performed quantitative bone histomorphometry on iliac-crest biopsies or autopsy material from 60 patients with chronic renal failure and found that although over half had an increase in osteoid only 40% showed typical osteomalacia, the incidence being even lower (27%) in the autopsy material. In 1973 Bordier et al (6) studied iliac crest biopsies from nine nephrectomized hemodialysis patients and found that eight did not show any evidence of osteomalacia. Moreover, in one patient in whom bone biopsy was obtained before and 10 months after bilateral nephrectomy, the osteomalacic changes present before nephrectomy had improved without any vitamin D 3 treatment (6). A few years later Kanis et al (7) found that only 16% of 93 patients with end-stage renal disease had osteomalacia, this frequency remaining unchanged among 49 of these patients who entered the chronic dialysis program.
In other studies, patients in chronic renal failure have been found to have decreased or undetectable levels of 1,25 (OH)2 D 3 but no evidence of osteomalacic lesions; furthermore, there was no correlation between the plasma levels of 1,25 (OH)2 D 3 and the degree of osteomalacia. This discrepancy has been observed not only in renal failure but also in osteomalacia without renal The International Journal Of Artificial Organs I Vol. 3 no. 6, 19801 p.p. 313-315 © by Wichtig Editore sri, 1980 failure. Thus, patients with anticonvulsant induced ostemalacia (8) have normal or even elevated plasma levels of 1,25 (OH)2 D 3 (3). Brooks et al (9) described a hypocalcemic patient with osteomalacia and secondary hyperparathyroidism in whom 25 hydroxyvitamin D s levels were elevated. Deluca (10) reported that the administration of vitamin D 3 to patients with vitamin Ds-dependent rickets may heal the rachitic changes and reverse biochemical abnormalities, despite the levels of 1,25 (OH)2 D s remaining low. Plasma concentrations of 1:25 (OH)2 D s were also low in the three patients with nutritional osteomalacia described by Eastwood et al (11) .
Similar conclusions emerge from the studies using 1,25 (OH)2 D s in the therapy of renal and non-renal osteomalacia. Brickman et al (12) , who treated nine patients with renal osteodystrophy, found that of the four with predominantly osteomalacic lesions the «osteoid width» was reduced only slightly in three; and that the calcification front improved in only two after 8 to 12 months of treatment. Pierides et al (13) , in a study of five patients with renal osteodystrophy, found healing in only two of the four patients with predominantly osteomalacic lesions: in the other two, treatment did not influence the number of osteoid filaments and in one patient the number of calcification fronts actually decreased. Also disappointing were the results of Kanis et al (7): of five uremic patients with predominantly osteitis fibrosa lesions three developed ostemalacic changes while on treatment. In an even more extensive study, Coburn et al (14) treated 46 patients with renal osteodystrophy with 1,25 (OH)2 D s and 1a, hydroxyvitamin D s for an average period of 22 weeks. Twenty-three of 37 patients had symptomatic improvement but 12 patients, four of whom had osteomalacia, failed to respond.
In the studies of Bordier et al (15) , 51 patients with non-renal osteomalacia were treated with phosphate (7) or vitamin D 3 (10),25 OH D 3 (17), 1,25 (OH)2 D s or 1a OH D 3 (13) and 24, 25 (OH)2 D s (4) for periods ranging from three weeks to three months. Vitamin D s and 25 OH D s produced significant improvement on the mineralization front; phosphate had no effect; and 1,25 (OH)2 Ds-1a OH Ds-and 24, 25 (OH)2 D 3 had only a minimal effect. Some patients who failed to respond to 1,25 (OH)2 D s showed an increase in the mineralization front after treatment with 25 OH D 3 . Similarly, a combination of 1,25 (OH)2 D 3 and 24, 25 (OH)2 D 3 proved more effective than either agent separately. later, Bordier and his colleagues (16) were unable to demonstrate that any of the hydroxylated products (1a OH D 3and 1a, 25 (OH)2 D 3 ) had therapeutic value in six patients with renal osteodystrophy treated for six weeks. According to Bordier et al (14) , healing of osteomalacia may require not only the mobilization of mineral from old bone by 1,25 (OH)2 D 3 but also (a) the retention of minerals in bone which is stimulated by 25 OH D 3 and (b) the direct effect of 25 OH D 3 (or one of its metabolites) on the osteocytes involved in bone mineralization.
Also supporting the findings of Bordier et al (15) are the studies of Berl et al (17) and of Pierratos et al (18) . In a double-blind controlled study, Berl et al (17) found that giving 1,25 (OH)2 D 3 to patients with renal osteodystrophy improved the skeletal lesions of secondary hyperparathyroidism but the osteomalacic lesions remained unchanged or became worse. Pierratos and his colleagues (18) treated eight patients with severe renal osteodystrophy with 1,25 (OH)2 D 3 for a period of 6 to 15 months. Three of their patients, who had predominantly osteomalacic lesions, showed no response to treatment.
Some reports in the literature, however, contradict these observations. Ahmed et al (19) reported that two patients with chronic renal failure and bone biopsies showing predominant osteomalacia responded to longterm treatment with small doses of 1.25 (OH)2 D 3 combined with 4 g CaC0 3 per day. Malluche et al (20) recently reported similar effects in 12 patients treated for six months with 1,25 (OH)2 D 3 . It is interesting, however, that of these 12 patients only one had predominant osteomalacia. Henderson et al (21) reported 11 patients and Silverberg et al (22) one patient said to have had osteomalacia, who were cured by 1.25 (OH)2 D 3 ; however, no bone histology was supplied and the radiological appearances were normal or showed mixed bone lesions.
It is apparent, nevertheless, that 1,25 (OH)2 D 3 does not playa dominant role in the etiology of osteomalacia, especially of renal origin, and that in most patients its absence does not produce the bony lesions of vitamin D 3 deficiency. Yet there is no good explanation for this failure of 1,25 (OH)2 D 3 to cure osteomalacia. It may be that another metabolite of vitamin D 3 is the osteotropic form which enhances bone mineralization, or perhaps that mineralization can occur only in the presence of an appropriate combination of the various D 3 metabolites. With respect to the former possibility, it has been suggested that 24, 25 (OH)2 D 3 enhances bone mineralization without increasing the intestinal absorption of calcium but this has not been confirmed (23) (24) . Similarly, it 314 has been reported that 25 OH D 3 is effective in curing patients with renal ostemalacia (27, 28) . Another possible cause of this failure is end-organ unresponsiveness to 1,25 (OH)2 D 3 . In addition, deposition of aluminum in bone or circulating inhibitors of calcification may prevent calcification despite administration of 1,25 (OH)2 D 3 (29, 30) . Finally, most patients with renal ostemalacia have low or undetectable levels of parathormone, a hormone that may be essential for the mineralization of the bone. Undoubtedly, the whole story of the relationship of vitamin D 3 and osteomalacia remains unclear, and many important questions must still be answered. When a patient develops chills and fever during dialysis (1) it has become traditional to blame endotoxin, a product of gram negative water bacteria, especially if subsequent blood cultures should remain negative. Yet, before deciding that endotoxin is the villain it is well to consider that its molecular weight is over 100,000 dalton and that molecules of this size would be expected to
